ArticleIntensive care medicine experimental2025
In vitro and in vivo muscle mass and strength during the first week of critical illness.
Article in Intensive care medicine experimental, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundLoss of muscle mass and strength is provoked by critical illness. Our primary aim was to study the development of muscle atrophy and weakness in vitro in isolated myofibers and in vivo muscle mass and in vitro muscle strength during the first week of critical illness. Furthermore, we explored how in vitro muscle strength compares to healthy controls. Finally, we studied correlations between in vitro muscle mass and strength and in vivo muscle mass in critically ill patients.
methodsWe performed a secondary analysis using data from a randomized controlled trial. We studied contractile force of single myofibers isolated from muscle biopsies around admission (day 1-3) and around 1 week after inclusion (day 8-10). Furthermore, we studied myofiber cross-sectional area (CSA), proportion of fast-twitch myofibers, bio-electrical impedance analysis-derived fat-free mass index (FFMI), ultrasound-derived quadriceps muscle layer thickness (QMLT) and diaphragm thickness. In the control group, only contractile force outcomes were available.
resultsIn total, ten ICU patients had two muscle biopsies taken. Maximum force of both fast and slow-twitch myofibers was reduced at day 8-10 compared to day 1-3, even though there were no differences in normalized force and calcium sensitivity. FFM and QMLT did not change over time, nor were there differences between groups. Compared to healthy controls, maximum force of myofibers was lower in the ICU group at day 8-10 in both slow and fast-twitch myofibers, while the calcium sensitivity of force was lower in slow-twitch myofibers. We found a significant correlation between myofiber CSA vs. FFMI (r = 0.68) and maximum force of the fast-twitch fibers vs. QMLT (r = 0.72).
conclusionsDuring the first week of critical illness, maximum force declined over time, while no other in vitro parameters changed. We found a moderate correlation between myofiber CSA vs. FFMI and maximum force of the fast-twitch fibers vs. QMLT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.